Author:
Gratzke Christian,Engel Jutta,Stief Christian G.
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.
2. Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the zometa european study (zeus). Eur Urol Suppl. 2013.
3. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A seer-based study. Eur Urol. 2013.
4. Frohmuller HG, Theiss M, Manseck A, Wirth MP. Survival and quality of life of patients with stage d1 (t1-3 pn1-2 m0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur Urol. 1995;27(3):202–6. Largest series to report the effect of radical prostatectomy on lymph-node positive patients with PCa.
5. Mitin T, Blute M, Lee R, Efstathiou J. Management of lymph node-positive prostate cancer: the role of surgery and radiation therapy. Oncology (Williston Park, NY). 2013;27(7):647–55.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献